Jonathan Strosberg

31PUBLICATIONS
83CO-AUTHORS
Molecular targetsPredictive and prognostic markersRadiation therapyGender studies not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Jan 12, 2026
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).

Jonathan R Strosberg, Tyler Zemla, Susan Geyer

|Nov 27, 2025
Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.

Jorge H Hernandez-Felix, Monica Isabel Meneses-Medina, Rachel Riechelmann

|Oct 01, 2025
Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors.

Taymeyah Al-Toubah, Eleonora Pelle, Mintallah Haider

|Sep 03, 2025
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Emily K Bergsland, Susan Geyer, Timothy R Asmis

|Jul 11, 2025
Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE.

Eleonora Pelle, Taymeyah Al-Toubah, Ghassan El-Haddad

Pageof 6